When Tumor Control Is Not Enough: Rituximab for Persistent Malignancy-Associated Membranous Nephropathy (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO1275; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "In this case, RTX given in a stepwise, response-guided manner, was safely co-administered with PRRT without interrupting oncologic therapy. Further studies are needed to define which patients with mMN may benefit from concurrent kidney-directed treatment."
Carcinoid Tumor • Glomerulonephritis • Oncology • Renal Disease • Solid Tumor • CHGA • NELL1
|
|
Jie Yao; Alwin Hwai Liang Loh; Hui Zhuan Tan
|